RxDoctor Payments Data

William Conkright, MD

Family Medicine · Augusta, GANPI 1609853191

Payments from drug & device makers

$15,082in general payments, 2019–2025

Across 968 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$871
  • Lilly USA, LLC$771
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$15,076100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,082 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$104,090
Medicare patients
258
Services billed
1,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$113,216
RybelsusSemaglutide47$62,376
EliquisApixaban63$60,473
MounjaroTirzepatide48$49,721
FarxigaDapagliflozin Propanediol40$42,678
JardianceEmpagliflozin20$24,844
Tresiba Flextouch U-200Insulin Degludec25$22,858
RexultiBrexpiprazole13$19,302
LinzessLinaclotide20$14,916
MyrbetriqMirabegron19$13,163
Victoza 2-PakLiraglutide16$9,498
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,342
Breo ElliptaFluticasone/Vilanterol16$5,658
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,449
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide141$4,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,190$175,591157 claims
PfizerEliquis$1,322$60,47363 claims
Lilly USA, LLCMounjaro$771$49,72148 claims
AstraZenecaFarxiga$1,266$42,67840 claims
Boehringer IngelheimJardiance$657$24,84420 claims
Otsuka America Pharmaceutical, Inc.Rexulti$337$19,30213 claims
AbbVieLinzess, Synthroid$1,794$18,07260 claims
GSKTrelegy Ellipta, Breo Ellipta$193$15,00028 claims
Astellas Pharma US IncMyrbetriq$275$13,16319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →